1Himmelfrb J,Hakim BM.Bicecmpabidity and risk of infection in tumodialys is patients.Nephrol Dial Transplant,1994,9:134-144.
2Haag-Weber,Horl MB.GIP and DIP:Anew view of uremic toxicity.Nephrol Dial Transplantb,1994,9:346-347.
3Oppermann M,Kinziz C,Ziezs R,et al.Elevated plasm level of the immusuppressive complement fragment Ba in renal failure.Kid Int,1991,40:939-947.
4Deppicch RM,Beek W,Crpehl H,et al.Complement comfoment as uremic toxins and their potential role as mediators of mizd inflammation.Kid Int,2001,59(Suppl 78):271-277.
5Guarniezi G,Toigo G,Fictt M,et al.Mechanism of malnubition in uremia.Kid Int,1997,53(Suppl 63):429-441.
6Okasha K,Saxena A,EL-Bedowey M,et al.Immunoglobulin aubclasses and subaptibility to allosensitization in humans.Clinical nephro,1997,18:165-172.
8Girndt M,Sester M,Sester V,et al.Molecular aspects of T-and B-cell function in mice.Kid Int,2001,59(Suppl 78):206-211.
9Brungger M,Hueter HN,Krapf R.Effect of chronic metabolic accidence on growth hormone/IGF endocrinic axis:new cause of growth hormone insensitivity in human.Kid Int,1997,51:216-221.
10Stencinkal P,Wanner C,Mestzcrer T,et al.Inflammation and outcome in end-stage renal failure:does female gender constitute a survival advantage.Kid Int ,2002,62:1791-1798.
